4D Molecular Therapeutics (FDMT) Receivables - Net (2019 - 2021)

4D Molecular Therapeutics (FDMT) has 3 years of Receivables - Net data on file, last reported at $47000.0 in Q4 2021.

• On a quarterly basis, Receivables - Net fell 95.73% year-over-year to $47000.0 in Q4 2021; TTM through Dec 2021 was $47000.0, a 95.73% decrease from a year earlier, with the FY2021 full-year figure at $47000.0, down 96.84% from the prior year.
• Receivables - Net for Q4 2021 stood at $47000.0, down from $800000.0 in the prior quarter.
• Over the last five years, Receivables - Net for FDMT reached as high as $1.2 million in Q2 2021 and fell as low as $47000.0 in Q4 2021.
• Historically, Receivables - Net has averaged $825000.0 across 3 years, with a median of $978000.0 in 2019.
• Across the five-year window, Receivables - Net grew 12.47% in 2020 and plunged 95.73% in 2021, its largest moves.
• Year by year, Receivables - Net stood at $978000.0 in 2019, then grew by 12.47% to $1.1 million in 2020, then plunged by 95.73% to $47000.0 in 2021.
• Per Business Quant data, the three most recent Receivables - Net figures were $47000.0 in Q4 2021, $800000.0 in Q3 2021, and $1.2 million in Q2 2021.